New President Appointed for Nitto Avecia Inc.

USA - English

• USA - Deutsch
• USA - Français
• USA - español

MILFORD, Mass., Aug. 3, 2018 /PRNewswire/ -- Nitto Denko Avecia Inc., the global leader in contract development and manufacturing of oligonucleotides for the therapeutic market announced today that Detlef Rethage will step down from the position of President of Nitto Denko Avecia Inc., effective July 16, 2018.  Mr. Rethage will continue to support the Nitto Avecia businesses as a corporate advisor in the period of transition.

Seiji Fujioka, Corporate Vice President, Director of the Medical Division of Nitto Denko Corporation("Nitto") has been appointed as President of Nitto Denko Avecia Inc.  Mr. Fujioka has served Nitto for 33 years and spent 15 years in the US with Nitto subsidiaries. Mr. Fujioka will have full responsibility for Nitto Denko Avecia Inc. and Nitto Avecia Pharma Services Inc. and will be located at the Nitto Denko Avecia Inc. headquarters in Milford, MA.

Seiji Fujioka stated that "Nitto will celebrate their centennial anniversary this year and is committed to investment in Life Science business through the New Mid-Term Plan. Milford, MA will be the center of the Medical Division as well as the center of Oligonucleotide excellence. Nitto Denko Avecia has experienced unparalleled growth and success in the oligonucleotide therapeutics business by supporting our customers' success from clinical development through commercial launch. Avecia grew over the last 12 years and became the market leader with four sites and more than 500 employees under Mr. Rethage's leadership.  We are looking forward to continuing to grow with our customers, partners, and team members by contributing to develop and commercialize these lifesaving innovative oligonucleotide based drugs."

ABOUT NITTO DENKO AVECIA INC.
Nitto Denko Avecia Inc. is a recognized leader in manufacturing and development services of oligonucleotide therapeutic with facilities located in Milford, MA.; Marlboro, MA.; and Cincinnati OH offering services for DNA, RNA and other oligonucleotides based therapeutics from milligram scale at pre-clinical stage to 1000kg + post commercial launch. More information: www.Avecia.com.

ABOUT NITTO DENKO CORPORATION

Founded in 1918, Nitto is Japan's leading materials manufacturer, offering over 13,500 diversified industrial products to more than 70 business fields as electronics, automobiles, ecology, and life science. Nitto Group will celebrate the 100^th anniversary of our foundation on October 25^th 2018. Over the next 100 years, Nitto aims to make people's lives healthier and comfortable all around the world. To make that happen, we will create new values in the business domains including life science and aspire to achieve our goal, "Nitto Everywhere – Where there are people's smiles, there is Nitto. More information: www.Nitto.com

For additional information, please contact:

Tammy Cooper, VP of Business Development, Nitto Denko Avecia Inc. [email protected]

SOURCE Nitto Avecia Inc.